MétaCan
Menu
← Back to cohort

L3 Effects on serum bile acids, pruritus, and safety with up to 72 weeks of odevixibat treatment: pooled data from the PEDFIC 1 and PEDFIC 2 studies in children with progressive familial intrahepatic cholestasis

2022· article· en· W4295254720 on OpenAlexaff
Kathleen M. Loomes, Henkjan J. Verkade, Richard J. Thompson, Binita M. Kamath, Winita Hardikar, Florence Lacaille, Yael Mozer‐Glassberg, Eyal Shteyer, Pier Luigi Calvo, Buket Dalgıç, Tassos Grammatikopoulos, Sanjay Rajwal, Jennifer Vittorio, Nisreen Soufi, Patrick McKiernan, Mary Elizabeth M. Tessier, Qifeng Yu, Lise Kjems, Patrick Horn

Bibliographic record

Venuenot available
Typearticle
Languageen
FieldMedicine
TopicDrug Transport and Resistance Mechanisms
Canadian institutionsHospital for Sick ChildrenUniversity of Toronto
Fundersnot available
KeywordsMedicineAdverse effectInternal medicinePlaceboGastroenterologyCholestasisBile acidPathology

Abstract

fetched live from OpenAlex

Introduction/Background Progressive familial intrahepatic cholestasis (PFIC) is a group of rare paediatric cholestatic liver diseases. In the phase 3 PEDFIC 1 and PEDFIC 2 studies, the efficacy and safety of odevixibat, an ileal bile acid transporter inhibitor, were examined in patients with PFIC. Aim Using pooled data from PEDFIC 1 and PEDFIC 2, we analysed changes in serum bile acids (sBAs) and pruritus and examined the safety profile of odevixibat in patients treated for up to 72 weeks, comparing those who responded to odevixibat treatment (Rs) with nonresponders (NRs). Subjects and Methods PEDFIC 1 was a 24-week, randomised, placebo-controlled study, and PEDFIC 2 is an ongoing 72 week extension study. This pooled, exploratory analysis spans from patients’ first dose of odevixibat to a data cut-off date of 4 December 2020. Patient pruritus was rated using the Albireo observer-reported outcome (ObsRO) instrument. Treatment Rs met either sBA response criteria (defined per the PEDFIC 1 study protocol; table 1) or sBA and/or pruritus response criteria (table 1). Safety assessments included evaluation of treatment-emergent adverse events (TEAEs). Results Overall, 84 patients received odevixibat (mean age, 5.0 years; median odevixibat exposure, 53 weeks). During weeks 0−72, 30/81 (37%) patients were sBA Rs and 49/84 (58%) patients were sBA and/or pruritus Rs. Mean changes in sBA levels from baseline to the last assessment in this analysis period, weeks 70−72, were –230 and −117 µmol/L in sBA Rs and NRs, respectively. From baseline to the last assessment interval in this analysis period, weeks 61−72, sBA Rs and NRs had mean changes in pruritus score of –2.2 and –0.9, respectively. Additional changes over time in sBAs and pruritus scores in patients meeting either criteria for treatment response are shown in the table 1. TEAEs were reported in 87% and 86% of sBA Rs and NRs, respectively, and in 86% and 83% of sBA and/or pruritus Rs and NRs. Two sBA Rs and 2 NRs (or 3 sBA and/or pruritus Rs and 2 NRs) had TEAEs leading to discontinuation. Summary and Conclusion Patients with PFIC who responded to odevixibat (based on protocol-defined response criteria) had sustained improvements in mean sBAs and pruritus scores over time. sBA Rs had larger improvements in pruritus than sBA NRs; pruritus improvements in those who did not meet sBA R criteria may reflect either perceived treatment effects or patients with a partial sBA R. Odevixibat treatment was generally well tolerated in both Rs and NRs.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame machine prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.

metaresearch head score (Codex)0.014
metaresearch head score (Gemma)0.013
Version: metacan-v3-hybrid-931329e0061cValidation status: machine_predicted_unvalidated
Candidate categoriesnone
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Meta-analysis · Consensus signal: none
GenreCandidate signal: Empirical · Consensus signal: Empirical
Teacher disagreement score0.014
Threshold uncertainty score0.075

Distilled classifier scores by category (both heads)

CategoryCodexGemma
Metaresearch0.0140.013
Meta-epidemiology (narrow)0.0010.001
Meta-epidemiology (broad)0.0050.011
Bibliometrics0.0020.002
Science and technology studies0.0000.001
Scholarly communication0.0020.001
Open science0.0010.001
Research integrity0.0020.001
Insufficient payload (model declined to judge)0.0030.000

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.022
GPT teacher head0.278
Teacher spread0.256 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.

The models applied no category: nothing in the taxonomy fit this work.
Study designMeta-analysis
Domainnot available
GenreEmpirical

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations0
Published2022
Admission routes1
Has abstractyes

Explore more

Same topicDrug Transport and Resistance Mechanisms→French-language works237,207→